Regeneron Pharmaceuticals (NASDAQ:REGN) reported strong financial results for the first quarter of 2026 on Wednesday, April 29, 2026, highlighted by high-double-digit revenue growth and significant regulatory milestones.
The Tarrytown-based biotechnology giant posted total revenue of $3.605 billion, representing a 19% increase year-over-year, as the company’s blockbuster portfolio continues to gain market share in the ophthalmology and immunology sectors.
The company reported GAAP diluted earnings per share (EPS) of $6.75, which included a $0.82 per share charge related to acquired in-process research and development (IPR&D).
On a non-GAAP basis, diluted EPS rose 15% to $9.47, reflecting strong operational performance across its core commercial assets.
During the period under reviewm Dupixent global net sales recorded by partner Sanofi reached $4.9 billion, a 33% increase year-over-year, driven by continued expansion into new indications and age groups.
Elsewhere, EYLEA HD U.S. net sales for the high-dose formulation surged 52% to $468 million.
The brand secured a pivotal regulatory win with the FDA approving EYLEA HD for extended dosing intervals of up to 20 weeks, further solidifying its competitive position in the wet age-related macular degeneration (wAMD) market.
In a historic move for the company’s genetic medicine pipeline, the newly approved gene therapy Otarmeni will be provided free of charge in the United States to eligible patients, underscoring Regeneron’s commitment to patient access for rare genetic conditions.